Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05585580 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date changed from estimate of Nov 1, 2025 to Apr 30, 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 7 of 7 sites
    v4
  2. Primary completion date: Nov 1, 2024 to Nov 1, 2025
    • Study completion date: Mar 1, 2025 to Nov 1, 2026
    v3
  3. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Start date changed from estimate of Nov 1, 2022 to Mar 1, 2023
    • Study sites: 6 to 7
    • Interventions: Lenvatinib (Drug), Paclitaxel (Drug), Serplulimab (Drug) to Lenvatinib (Drug), Paclitaxel/Paclitaxel-albumin/Paclitaxel liposome (Drug), Serplulimab (Drug)
    • Eligibility criteria expanded, about 8 words
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a prospective, single arm, multicenter phase II study to assess the effectiveness of Serplulimab, Lenvatinib and Paclitaxel in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma after first-line immunotherapy.
Trial Details
NCT Number NCT05585580
Lead Sponsor Qilu Hospital of Shandong University
Conditions
(from sponsor)		 Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Enrollment 59 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov